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Abstract
Glutamine synthetase (GS) generates glutamine from glutamate
and controls the release of inflammatory mediators. In macro-
phages, GS activity, driven by IL10, associates to the acquisition
of M2-like functions. Conditional deletion of GS in macrophages
inhibits metastasis by boosting the formation of anti-tumor,
M1-like, tumor-associated macrophages (TAMs). From this basis,
we evaluated the pharmacological potential of GS inhibitors in
targeting metastasis, identifying glufosinate as a specific human
GS inhibitor. Glufosinate was tested in both cultured macro-
phages and on mice bearing metastatic lung, skin and breast
cancer. We found that glufosinate rewires macrophages toward
an M1-like phenotype both at the primary tumor and meta-
static site, countering immunosuppression and promoting vessel
sprouting. This was also accompanied to a reduction in cancer
cell intravasation and extravasation, leading to synchronous
and metachronous metastasis growth inhibition, but no effects
on primary tumor growth. Glufosinate treatment was well-
tolerated, without liver and brain toxicity, nor hematopoietic
defects. These results identify GS as a druggable enzyme to
rewire macrophage functions and highlight the potential of
targeting metabolic checkpoints in macrophages to treat cancer
metastasis.
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Introduction
Tumor-associated macrophages (TAMs) constitute the main stromal
compartment in many tumors. TAMs support different crucial func-
tions for cancer progression by shaping adaptive immune responses
and by contributing to vessel and matrix remodeling, cancer cell
proliferation, survival, and metastasis (Noy & Pollard, 2014; Singh
et al, 2017). At the metastatic site, macrophages (that are metastasis-
associated macrophages, MAMs) can also favor the preparation of
the pre-metastatic niche and cancer cell extravasation (Gil-Bernabé
et al, 2012; Sharma et al, 2015; Lin et al, 2019). For these reasons,
targeting macrophage functions is now considered a promising strat-
egy to harness primary and metastatic tumor growth. More evidence
on TAMs suggests but does not always prove that these diverse func-
tions are driven and sustained by distinct metabolic states (Mazzone
et al, 2018; Flerin et al, 2019; Castegna et al, 2020). The classical
pro-inflammatory and antitumoral macrophage phenotype can be
resembled by in vitro stimulation with lipopolysaccharide (LPS)/
interferon-c (IFN-c), whereas the alternative, pro-tumor function is
achieved by IL4 and IL10. These cytokines are responsible for meta-
bolic shifts that underline defined functional states in
macrophages (Biswas & Mantovani, 2012; Mills & O’Neill, 2016).
More information is awaited regarding the role of specific metabolic
features affecting TAM behavior in vivo, the strategies to rewire their
protumoral phenotype toward their original protective, anti-tumor
function, and their impact on disease outcome (Wenes et al, 2016;
Palmieri et al, 2017b). In the effort to dissect which pathways under-
line the phenotypic switch in TAMs, we have discovered that target-
ing glutamine synthetase (GS; a.k.a. glutamate ammonia ligase,
GLUL, EC 6.3.1.2) in macrophages represents an effective way to
reprogram in vitro IL10-stimulated macrophages and TAMs toward a
desirable “M1-like function”. GS-inhibited IL10 macrophages display
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typical M1-like features both metabolically and functionally, with an
increased glycolytic flux partly linked to HIF1a stabilization,
enhanced ability to impair cancer invasion, reduced capacity to
induce angiogenesis, and enhanced propensity for T-cell activation
and recruitment. This ultimately results in metastasis inhibition in
tumor-bearing mice (Palmieri et al, 2017b). These encouraging
results have prompted us to pursue inhibition of GS in macrophages
as an immunometabolic strategy to reduce metastasis in cancer.
Methionine sulfoximine (MSO) is the classical GS inhibitor
through irreversible binding to the glutamate site, but many studies
have been performed on different classes of molecules able to inhibit
GS, with particular attention to plant GS, in which inhibition of gluta-
mine synthesis has been proved particularly effective in killing
weeds (Occhipinti et al, 2010). Glufosinate, or phosphinothricin
[CAS Number: 51276-47-2], is a non-proteinogenic amino acid that
inhibits GS in bacteria (Bayer et al, 1972), algae (Hall et al, 1984),
and higher plants (Leason et al, 1982). Studies in rats have shown
that pharmacological inhibition of GS by glufosinate ammonium is
lethal at very high doses (LD50 1,500–2,000 mg/kg); however, our
understanding on the systemic toxicity of this molecule (e.g., TD50
studies) remains sparse and not conclusive (Cox, 1996). Glufosinate
is a glutamate analogue and competes with glutamate for the binding
in the active site (Logusch et al, 1989). The effect of glufosinate on
human GS has never been proven, but the specificity of its inhibitory
action in plant GS (Occhipinti et al, 2010) prompted us to test its
effect on the human recombinant GS as well as in macrophages both
in vitro and in vivo. Our results point to a significant inhibitory
capacity of glufosinate toward human GS. Furthermore, at micromo-
lar concentrations glufosinate treatment induces a shift from a M2-
like to an M1-like phenotype in murine and human macrophages
similarly to the effect displayed by MSO. This rewiring is associated
with a decreased immunosuppression, angiogenesis, and metastatic
burden in murine models of lung, breast cancer, and melanoma
treated with glufosinate, similarly to what observed in the macro-
phage-specific GS knockout mice (Palmieri et al, 2017b), without
any sign of specific liver or brain toxicity nor hematopoietic abnor-
malities at all tested doses.
In the clinic, cancer death is mostly due to the appearance of dif-
fused metastatic lesions that can be treated together with the
primary tumor when the latter is unresectable or already in
advanced stages (synchronous metastasis). Alternatively, metastasis
treatment can start few or several years after primary tumor resec-
tion following the relapse of the disease far from the original site
(metachronous metastasis) (Mekenkamp et al, 2010). The data
hereby presented show that the antimetastatic effect of glufosinate
is evident not only in a synchronous setting but also in a metachro-
nous setting, increasing the clinical potential of our findings. This
study provides a proof-of-concept of the role of in vivo pharmaco-
logical GS inhibition as immunometabolic strategy to reduce metas-
tasis and highlights the significance of in vivo targeting of
macrophagic metabolic checkpoints as a promising alternative to
tackle tumor progression and metastasis.
Results
Glufosinate inhibits human recombinant GS
The enzyme activity of the human recombinant GS (hGS), obtained
by its expression in E. coli (Fig 1A), was evaluated in the presence of
saturating concentrations of substrates for almost 90 min at 25°C and
was found to be linear at least for 10 min at 25°C (Fig 1B). The
Michaelis–Menten (half-saturation) constant (Km) of the human
recombinant GS was determined by measuring the initial rate by vary-
ing L-glutamate or ATP concentrations in presence of a fixed saturat-
ing concentration of the other two substrates. By Lineweaver–Burk
plots, the Km and Vmax values were 1.42  0.17 mM and 0.82 
0.05 lmol/min/mg protein for L-glutamate, and 2.56  0.15 mM and
0.91  0.03 lmol/min/mg protein for ATP (Fig 1C and D).
The effect of glufosinate on GS activity was investigated and was
compared to that displayed by MSO on the human recombinant
protein. Glufosinate and MSO inhibited human recombinant GS in a
concentration-dependent manner (Fig 1E). Interestingly, glufosinate
inhibition was much more effective compared to that of MSO as
▸Figure 1. Glufosinate specifically inhibits human recombinant GS.A Expression in E. coli and purification of human GS (hGS). Protein was separated by SDS–PAGE and stained with Coomassie Blue dye. M: marker Precision Plus
Protein Dual Color Standard (Bio-Rad). From right Lanes 1–4: E. coli Bl21(DE3) cells containing the expression vector without (lanes 1 and 2) and with (lanes 3 and
4) the coding sequence of hGS. Samples were taken immediately before (lanes 1 and 3) and 3.5 h later (lanes 2 and 4) the induction of expression with isopropyl-
b-D-1-thiogalattopiranoside (IPTG) 0.7 mM. The same number of bacteria was analyzed in each sample. Lane 5: isolated and purified inclusion bodies (4 lg).
Adjacent boxed lane: Western blotting analysis of GS.
B–E Kinetic study of the reaction catalyzed by recombinant hGS. The reaction, started by adding ATP, was linear for at least 10 min at 25°C (B). Lineweaver–Burk plot
reporting the hGS activity at the indicated concentrations of glutamate in the absence ( ), or in the presence of glufosinate (C) or MSO (D). Symbols ( ): 2 mM
MSO or 0.025 glufosinate; ( ) 3 mM of MSO or 0.050 mM of glufosinate; ( ) 4 mM of MSO or 0.065 mM of glufosinate; ( ) 5 mM of MSO or 0.075 mM of
glufosinate. The insets represent the secondary plot of the slopes of Lineweaver–Burk plot obtained at the indicated concentrations of glufosinate (C) or MSO (D)
used for determining the inhibitor constant Ki. GS inhibition (%) in presence of increasing concentrations of glufosinate ( ) or MSO ( ) results from the average
of at least three independent experiments (E). The control value for uninhibited hGS activity is 0.51  0.08 lmol/(min × mg protein).
F–K Comparative analysis of GS structures from several organisms. Lateral (F) and top view (G) of the entire GS decameric (a dimer of pentamers) structure are reported
in pink cartoon representation. (H) Cartoon representation showing the top view of the monomer–monomer interface hosting cofactors, substrates, or inhibitors
(Dataset EV1) participating to or inhibiting the conversion of glutamate to glutamine. In particular, ADP (cyan), phosphate ions (brown), MSO phosphate (P3S,
yellow), phosphoaminophosphonic acid-adenylate ester (ANP, white), glutamate (magenta), citrate (black), and the imidazopyridine inhibitor ((4-(6-bromo-3-
(butylamino)imidazo(1,2-a)pyridin-2-yl)phenoxy) acetic acid, green) are reported in sticks representation, whereas Mn2+ ions are reported in pale blue spheres and
Mg2+ in pale green spheres (involved in the coordination of the imidazopyridine inhibitor). (I) Superimposition of all the sampled 17 crystallized structures (Dataset
EV1). (J) 2D representation of glutamate, P3S, glufosinate, and glyphosate. (K) Zoomed view of the crystallized P3S binding region and the docked glufosinate and
glutamate binding regions within the superimposed human (white cartoon) and Z. mays (pink cartoon) GS structures.
Source data are available online for this figure.
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showed by the IC50 values that are of 0.051 and 2.4 mM, respec-
tively (Fig 1E).
To shed light into the inhibition mechanism, double-reciprocal
plots were obtained from the reciprocal of initial rates versus
the reciprocal of L-glutamate with or without different concentra-
tions of MSO or glufosinate. The initial binding of glufosinate
(Fig 1C) or MSO (Fig 1D) to human GS was competitive versus
glutamate. The Ki value for MSO, estimated by secondary plot,
was 0.88 mM in good agreement with the value previously
obtained (Jeitner & Cooper, 2014) (inset of Fig 1D). Furthermore,
the Ki value of glufosinate was estimated about 0.0195 mM (in-
set of Fig 1C) confirming a greater selectivity of this inhibitor
when compared to that of MSO.
To rule out an additional off-target role of glufosinate, a sequence
database screening was performed by using alternatively H. sapiens
or Z. mays GS sequences, searching for highly similar paralogous
sequences in mammalia and plants (Dataset EV1). This search
revealed no significant similarity between the query GS sequences
and other mammalia or plant paralogous sequences, different from
GS, nor identified structurally related proteins, beyond the available
GS proteins, in the PDB until today (Dataset EV2).
For gaining new insights about glufosinate competitive bind-
ing mechanism to GS binding region, in presence of glutamate,
the available crystallized structures were manually inspected by
using 3D visualizer. Thus, it was observed that several ligands
participating in the reaction catalyzed by GS were crystallized in
complex at the monomer–monomer interface with GS (Fig 1F–K),
namely ADP, phosphate ion, L-methionine-S-sulfoximine phos-
phate (P3S), phosphoaminophosphonic acid-adenylate ester
(ANP), glutamate, citrate, and the imidazopyridine inhibitor ((4-
(6-bromo-3-(butylamino)imidazo(1,2-a)pyridin-2-yl)phenoxy)
acetic acid) (Dataset EV2). Given the structural similarity of
glufosinate with glutamate ligand and P3S, after superimposition
of the three molecules in the GS catalytic site, it is observed
that glufosinate might bind most of residues involved in the
binding of glutamate ligand (in 4hpp.pdb) and P3S (i.e., in
2qc8.pdb) (Fig 1F–K and Dataset EV3).
Glufosinate skews macrophages away from an M2-like
phenotype and promotes an M1-like phenotype in vitro
Based on the inhibitory capacity of glufosinate on the human
recombinant protein, together with our previous findings on the
role of GS in macrophages (Palmieri et al, 2017b), we asked
whether pharmacological GS targeting affects polarization of
primary human macrophages. To this end, macrophages derived
from human monocytes were skewed toward an M2-like pheno-
type with IL10 in presence or absence of glufosinate and the
expression levels of M1 and M2 markers were measured. In
IL10-stimulated macrophages (IL10-macrophages for simplicity),
M1-like genes, such as CD80, CXCL9, and CXCL10 (Fig 2A–C),
were upregulated by glufosinate in a concentration-dependent
fashion, except for TNFA, which strongly increased only at
20 lM concentration (Fig 2D). Concomitantly, up-regulation of
M2-specific markers upon IL10 stimulation, such as MSR1
(CD204) and MRC1 (CD206), CCL17 and CCL18, was reduced
(Fig 2E–H). These data indicate that glufosinate effectively
blocks GS activity in macrophages and this prevents the expres-
sion of M2 markers while promoting the acquisition of M1
features, in a more effective fashion compared to MSO
(Palmieri et al, 2017b). From a metabolic point of view, glufosi-
nate/IL10 macrophages displayed increased glutamate and succi-
nate levels, with a decrease in glutamine compared to IL10
macrophages (Fig EV1A), phenocopying the metabolic repro-
gramming displayed by MSO-treated IL10 macrophages (Palmieri
et al, 2017b).
▸Figure 2. Glufosinate promotes a rewiring of IL10macrophages toward a M1-like phenotype through HIF1a stabilization and abolishes immunosuppressiveeffect of hypoxia.
A–D Evaluation of M1 markers in macrophages by real-time PCR. Fold change of TNFA, CD80, CXCL9, and CXCL10 mRNA in IL10, MSO- and glufosinate (10 and 20 lM)-
stimulated IL10 macrophages (n = 3).
E–H Evaluation of M2 markers in macrophages by real-time PCR. Fold change of MRC1, MSR1, CCL17, and CCL18 mRNA in IL10, MSO-, and glufosinate (10 and 20 lM)-
stimulated IL10 macrophages (n = 3).
I–M Evaluation of M1 markers in macrophages following HIF1a inhibition by real-time PCR. Fold change of TNFA, CXCL10, CD86, CD80, and CXCL9 mRNA in IL10 alone
or glufosinate (10 and 20 lM)- and acriflavine/glufosinate (10 and 20 lM)-IL10 macrophages (n = 3).
N–P Evaluation of M2 markers in macrophages following HIF1a inhibition by real-time PCR. Fold change of MRC1, MSR1, and CCL18 mRNA in IL10, glufosinate (10 and
20 lM)-treated, and acriflavine/glufosinate (10 and 20 lM)-treated IL10 macrophages (n = 3).
Q Quantification of cancer cell motility through a matrigel-coated membrane in presence of IL10, MSO/IL10, and glufosinate (10 and 20 lM)-IL10-treated
macrophages after 24 h of incubation (n = 6).
R Evaluation of the capillary network formation in presence of macrophages pretreated for 24 h with IL10 or MSO/IL10, and glufosinate (10 and 20 lM)/IL10 after
4 h of incubation with HUVEC cells (n = 6).
S CD8+ T-cell suppression by macrophages treated with IL10 or MSO/IL10, and glufosinate (10 and 20 lM)/IL10 for 24 h (n = 4). Proliferation was evaluated by
reading radioactivity as cpm (counts per minute), after incubation with 1 lCi/well tritiated thymidine. The proliferation of T cells cultured without macrophages
was used as control.
T CD8+ T-cell recruitment in a transwell system by macrophages treated with IL10 or MSO/IL10, and glufosinate (10 and 20 lM)/IL10 for 24 h versus macrophages
treated with LPS/IFNc; the migration of T cells cultured without macrophages (Mφ-) in presence of CXCL10 was used as positive control (n = 4).
U Representative image of Western blotting analysis of HIF1a, REDD1, 4E-BP1, S6, and P70S6K (in their phosphorylated and unphosphorylated form) to test mTOR
activation in normoxic (NRX) and hypoxic (HYP) IL10 macrophages treated with glufosinate (20 lM), rapamycin (20 nM) and a combination of both (n = 3).
V CD8+ T-cell suppression by normoxic and hypoxic IL10 macrophages treated with glufosinate (20 lM), rapamycin, and a combination of both for 24 h (n = 4).
Proliferation was evaluated by reading radioactivity as cpm (counts per minute), after incubation with 1 lCi/well tritiated thymidine. The proliferation of T cells
cultured without macrophages was used as control.
Data information: Data are reported as means  SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Exact P values and statistical tests are reported for each
experiment in Appendix Table S2.
Source data are available online for this figure.
4 of 24 EMBO Molecular Medicine 12: e11210 | 2020 ª 2020 The Authors
EMBO Molecular Medicine Alessio Menga et al
A B C D E F
G H I J K






ª 2020 The Authors EMBO Molecular Medicine 12: e11210 | 2020 5 of 24
Alessio Menga et al EMBO Molecular Medicine
Glufosinate-treated macrophages display HIF1a activation and
relevant anti-tumor functions in vitro
Since glufosinate promotes succinate accumulation and skews IL10
macrophages toward an M1-like phenotype, which is characterized
by succinate accumulation (Fig EV1A), we tested whether HIF1a,
known to be stabilized by succinate (Tannahill et al, 2013), is
upstream to the expression of a pro-inflammatory M1 phenotype
(Takeda et al, 2010). Treatment with the HIF1a inhibitor acriflavine
prevented the M2 to M1 phenotypical rewiring in glufosinate-treated
IL10 macrophages, since the expression of typical markers of classi-
cally activated macrophages (such as TNFA, CXCL10, CD86, CD80,
and CXCL9) was significantly decreased (Fig 2I–M). Concomitantly,
acriflavine reduced the expression of markers expressed in IL10
macrophages such as MRC1, MSR1, and CCL18 (Fig 2N–P). This
trend was confirmed at the protein level for TNFa and CCL18
(Fig EV1B). Since it is known that M2-like macrophages support
cancer cell migration (Joyce & Pollard, 2009), we evaluated the
extent of cancer motility through 8 lm-pores in presence of macro-
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and then washed out. In line with the finding that glufosinate
hinders M2-like features, A549 human lung cancer cells in the pres-
ence of glufosinate/IL10 macrophages were significantly less motile
in a concentration-dependent fashion in comparison to cells exposed
to IL10-stimulated control macrophages (Figs 2Q and EV1C).
Finally, we assessed the capillary network formation in response
to M2-like macrophages with or without glufosinate. Compared to
IL10 macrophages, macrophages pre-stimulated with IL10 and
glufosinate were less effective in promoting capillary formation,
suggesting that glufosinate hinders in a concentration-dependent
fashion the ability of IL10 macrophages to sustain vessel sprouting
(Figs 2R and EV1D).
We then tested the role of glufosinate in modulating CD8+ T-cell
proliferation and migration. To this end, we treated IL10 macro-
phages with vehicle, MSO, or glufosinate, and after washing the
treatment out, we reseeded each condition with autologous CD8+ T
cells. Upon 24 h stimulation, IL10 macrophages displayed the stron-
gest effect in suppressing the proliferation of cocultured CD8+ T
cells. Glufosinate blunted T-cell suppression imposed by IL10
macrophages in a concentration-dependent fashion and more effec-
tively than MSO, as shown by CD8+ T-cell proliferation partial
rescue when glufosinate (or MSO)-stimulated IL10 macrophages
were cocultured with pre-activated T cells (Fig 2S). To quantify
T-cell adhesion and chemotaxis, CD8+ lymphocytes were cultured
alone, in the presence of CXCL10, LPS/IFNc, IL10, MSO/IL10, and
glufosinate/IL10 macrophages. T-cell chemotaxis through a 5 lm
pore membrane was promoted by CXCL10 or by M1 macrophages,
but not by IL10-macrophages and the condition without macro-
phages (Fig 2T). However, when cultured with glufosinate-treated
IL10 macrophages, T cells were recruited and were able to
migrate to a similar extent as those cultured with LPS/IFNc
macrophages (Fig 2T).
Although stabilization of HIF1a in normoxic macrophages is
known to sustain a pro-inflammatory, M1-like phenotype (Tannahill
et al, 2013), in hypoxia HIF1a is exploited by TAMs to suppress T
cells via iNOS induction (Doedens et al, 2010). In oxygen and nutri-
ent-replete conditions, TORC1 is known to sustain a pro-inflamma-
tory phenotype (Byles et al, 2013; Zhu et al, 2014; Moon et al,
2015). However, under hypoxia, mTOR signaling is turned off and
this occurs partly via the transcriptional induction of REDD1 (Wenes
et al, 2016). We hypothesized that GS inhibition in hypoxic macro-
phages leads to mTOR re-activation via REDD1 blockade (Mazzone
et al, 2018), ultimately promoting the acquisition of normoxic M1-
like features linked to HIF1a stabilization (and TORC1 signaling) in
macrophages. Indeed, REDD1 protein levels were higher in IL10
hypoxic versus normoxic macrophages, leading to mTOR inhibition
(Fig 2U). However, glufosinate treatment reverted this effect, as
REDD1 protein levels decreased and mTOR got activated despite
hypoxia (Fig 2U). This eent promoted the acquisition of classical
normoxic M1-like features of IL10-macrophages that, even in
hypoxic conditions, still sustain T-cell activation to a significantly
higher extent compared to IL10 macrophages (Fig 2V).
Hence, glufosinate prevents the protumoral effects of IL10-
stimulated macrophages by improving CD8+ T-cell proliferation and
migration, and by inhibiting capillary formation and cancer
cell invasion.
Glufosinate treatment inhibits metastasis in different
cancer types
In order to translate our findings in mouse models of cancer, we
first assessed the effects of glufosinate in murine macrophages
isolated from BMDMs. Similar to the results on human IL10 macro-
phages, glufosinate/IL10 murine macrophages displayed upregu-
lated M1 markers, such as Tnfa, Cxcl10, and Nos2 (Fig EV2A).
Glufosinate blocked the up-regulation of M2-specific markers
following IL10 stimulation, such Ccl22 and Arg1, the latter display-
ing a more significant reduction at increasing glufosinate concen-
trations (Fig EV2B). Coculture experiments with Lewis lung
carcinoma (LLC) cells showed that glufosinate impaired the effect
of murine IL10 macrophages on LLC proliferation and migration
(Fig EV2C and D), although the concentrations of glufosinate used
did not exert any differential effect. Glufosinate treatment directly
on LLC cells did not show an effect on proliferation and migration
both in normal medium and under glutamine deprivation
(Fig EV2E). These results were obtained also with 4T1 breast
cancer (Fig EV2F) and YUMM1.7 melanoma cells (Fig EV2G), used
in further in vivo experiments.
Therefore, we tested the effect of glufosinate on mice bearing dif-
ferent cancer types. As a lung cancer model, LLC cells were
implanted subcutaneously in C57Bl/6J mice and followed for tumor
growth (Fig 3A). Glufosinate levels, measured within the tumor
mass, were increased in a concentration-dependent fashion up to
20 mg/kg, above which saturation occurred (Fig 3B). Given the
saturation in intratumoral glufosinate levels reached at 20 mg/kg,
we decided to test the in vivo efficacy of GS inhibition at 10 and
20 mg/kg only. Glufosinate reduced glutamine levels in tumors
(Fig 3C) and plasma (Fig EV2H) in a dose-dependent manner,
◀ Figure 3. Glufosinate treatment induces an M1-like phenotype and inhibits metastasis.A Experimental plan. Mice were subcutaneously injected with LLC cells. When the tumor reached 80–100 mm3 size, mice were treated by gavage with glufosinate
(10, 20, and 40 mg/kg) for 14 days.
B, C Quantification of glufosinate (B) and glutamine (GLN) (C) levels in wet tumor tissues of vehicle and glufosinate-treated mice (n = 8), by liquid chromatography–
mass spectrometry (LC-MS).
D, E Subcutaneous LLC tumor growth over the time (D) and number of lung metastatic nodules in vehicle and glufosinate (10 and 20 mg/kg)-treated mice (E) (pool of 2
independent experiments; 10 mice per condition in total).
F–H Quantification and representative images of F4/80+ CD11c+ cells in the lung metastasis (F), F4/80+ CD206+ (G) and F4/80 CD11c+ (H) cells infiltration in tumors of
vehicle and glufosinate-treated mice (n = 6).
I, J RT–PCR quantification of M2 (Ccl22, Arg1, and Ccl17) (I) and M1 (Tnfa, Cxcl9, Nos2, Cd86, and Cd80) (J) markers in vehicle and glufosinate-treated mice (n = 4).
Data information: In each histological quantification, n represents the number of animals. Six images per tumor were analyzed. Scale bars: 20 lm (F), 50 lm (G, H). Data
are reported as means  SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Exact P values and statistical tests are reported for each experiment in
Appendix Table S2.
Source data are available online for this figure.
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without showing any effect on GS expression (Fig EV2I). Although
tumor volumes and weights were unchanged (Figs 3D and EV2J),
metastases in glufosinate-treated versus untreated mice were signifi-
cantly decreased (Fig 3E). We then characterized the features of the
macrophage infiltrate at the tumor and metastatic sites by analyzing
expression of the M1 marker CD11c and the M2-like marker CD206
(MRC1) in F4/80+ cells (Rolny et al, 2011). Although overall F4/
80+ macrophage infiltration in the tumor or in the metastasis was
comparable in treated versus untreated mice (Fig EV2K and L), we
confirmed that both TAMs and MAMs in treated LLC tumor-bearing
mice were prevalently CD11chigh (Fig 3F and H) and that TAMs in
treated LLC tumor-bearing mice were prevalently CD206low
(Fig 3G). Furthermore, qPCR analysis showed that TAMs sorted
from glufosinate-treated mice displayed a lower expression of the
M2-specific marker Ccl22, Arg1, and Ccl17 (Fig 3I), and an
increased expression of the M1-specific markers Tnfa, Cxcl9, Nos2,
Cd86, and Cd80 (Fig 3J). Overall, these data indicate that glufosi-
nate skews both TAMs and MAMs away from the M2-like pheno-
type in favor of more M1-like features.
We also investigated the tumor vasculature and T cells since a
shift in macrophage phenotype should impinge on angiogenesis and
adaptive immunity (Rolny et al, 2011). Indeed, both blood vessel
length and area were reduced in glufosinate-treated versus
untreated tumors (Fig 4A and B). However, tumor vessels in glufos-
inate-treated mice displayed increased vascular coverage and perfu-
sion as shown, respectively, by an increased expression of a-smooth
A
D
F G H I
E
B C
Figure 4. Glufosinate treatment induces CTL accumulation and tumor vessel normalization.
A–C Quantification of total length of vessels (A), of CD31+ tumor vessel area (B), and of aSMA+ pericyte-covered vessels over the total number of CD31+ vessels (with
representative images) (C) in vehicle and glufosinate (20 mg/kg)-treated mice (n = 6).
D Quantification and representative images of lectin+ tumor vessel area over the total number of CD31+ vessels in vehicle and glufosinate (20 mg/kg)-treated mice
(n = 6).
E Quantification and representative images of PIMO+ tumor hypoxic areas in vehicle and glufosinate (20 mg/kg)-treated mice (n = 6).
F–H FACS quantification of TCRbeta+ CD8+ cytotoxic T cells in tumors of vehicle and glufosinate-treated mice (F). Evaluation of CD69 (G) and CD25 (H) proteins,
expressed as mean fluorescence intensity (MFI), was determined by flow cytometry on the surface of responders CD8+ T cells (n = 4).
I Quantification of secreted IFNc in interstitial tumoral fluid of vehicle and glufosinate-treated mice (n = 6).
Data information: In each histological quantification, n represents the number of animals. Six images per tumor were analyzed. Scale bars: 50 lm. Data are reported as
means  SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Exact P values and statistical tests are reported for each experiment in Appendix Table S2.
Source data are available online for this figure.
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muscle actin (a-SMA) (Fig 4C), increased lectin perfusion (Fig 4D),
and reduced tumor hypoxia (Fig 4E), all signs of tumor vessel
normalization (Mazzone et al, 2009).
When quantifying T-cell infiltration by fluorescence-activated cell
sorting (FACS) in glufosinate-treated versus untreated mice, we
observed that glufosinate enhanced the infiltration and the activation
of CD8+ T cells (Fig 4F) as indicated by a significant up-regulation of
CD69 and CD25 expression (Fig 4G and H). Furthermore, intratu-
moral IFNc was significantly higher in glufosinate-treated versus
untreated mice (Fig 4I). In contrast, intratumor infiltration of CD4+ T
cells did not change (Fig EV2M). Altogether, these data demonstrate
that glufosinate treatment in LLC-bearing mice reduces metastasis by
hindering the angiogenic, immunosuppressive, and pro-metastatic
potential of TAMs. A similar effect on tumor growth and metastasis
was obtained when C57Bl/6N mice were treated with the ammonium
salt of glufosinate (Fig EV2N and O).
To study and dissect the effect of glufosinate on cancer cell
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(synchronous metastasis) compared to the effect of glufosinate on
disease relapse and metastatic growth in the absence of a primary
tumor (metachronous metastasis), LLC tumors were surgically
resected (at an average size of 300–400 mm3) 10 days after subcuta-
neous implantation and mice were treated 14 days after resection
with glufosinate (20 mg/kg) until the end stage (Fig 5A). Change in
body weight following glufosinate treatment was not observed
(Fig 5B). We found that the total metastatic area analyzed on H&E-
stained lung sections was reduced (Fig 5C and D), with an increased
incidence of metastatic lesions smaller than 0.5 mm2 and a
decreased incidence of those bigger than 1.0 mm2 in glufosinate-
treated versus untreated mice (Fig 5D). Overall, our data suggest
that glufosinate hampers metastasis formation by likely preventing
cancer cell intravasation, extravasation, and metastatic growth (that
is a preventive mechanism of action on metastasis formation).
Since GS is expressed by other cells in the TME, glufosinate-
mediated GS inhibition in these cells cannot be excluded. To study
the relevance of non-macrophagic GS blockade by glufosinate in the
inhibition of metastasis, we tested the effect of glufosinate in LLC-
bearing mice treated with an anti-CSF1R antibody to almost
completely prevent intratumor infiltration of TAMs (Fig 5E). Glufos-
inate did not affect tumor volume (Fig EV3A) and weight
(Fig EV3B) either with or without anti-CSF1R. Anti CSF1R treatment
significantly depleted TAMs (Fig EV3C and D). However, glufosi-
nate was able to inhibit metastasis only in absence of anti-CSF1R,
while TAM depletion by anti-CSF1R completely neutralized glufosi-
nate effects on metastasis (Fig 5F and G), thus following the same
trends observed on CTCs (Fig EV3E). In contrast, the effect of
glufosinate on blood vessels was maintained also when TAMs were
depleted (Fig EV3F and G), pointing to a direct anti-angiogenic
effect on GS inhibition on endothelial cells even in absence of
vessel-remodeling macrophages. These findings clearly indicate that
TAM rewiring toward an M1-like phenotype, rather than TAM
depletion, effectively reduces tumor metastasis. Overall, these
results show that the antimetastatic effect of glufosinate occurs
mainly through macrophages.
To investigate its role in preventing immune suppression and
reducing the metastatic burden in a melanoma model, glufosinate
was administered to CD90.2+ C57BL/6 mice injected orthotopically
(intradermally) with YUMM1.7 melanoma cells, expressing the
◀ Figure 5. Glufosinate impairs metastatic growth after LLC tumor resection.A Experimental plan. Mice were subcutaneously injected with LLC cells. When the tumor reached 300–400 mm3 size, mice were tumor resected. 14 days after
resection, mice were treated by gavage with glufosinate (20 mg/kg) for 14 days.
B Evaluation of body weight in vehicle and glufosinate (20 mg/kg)-treated mice (n = 8).
C Representative images of metastasis at the beginning and end of therapy. Evaluation of the metastatic burden following glufosinate treatment by H&E staining
(n = 8).
D Evaluation of lung total metastatic area and of lung metastatic lesions per size by H&E staining in vehicle and glufosinate (20 mg/kg)-treated mice (n = 8).
E Experimental plan for macrophage depletion setting. Mice were preconditioned for 3 days by i.p. injection with anti-CSF1R antibody (or isotype IgG control) before
LLC (CD90.1+) tumor cell injection and then injected 3 times a week until sacrifice. When the tumor reached 80–100 mm3, mice were treated by gavage with
vehicle or glufosinate (20 mg/kg) for 14 days.
F, G Quantification (F) and representative images (G) of total metastatic area in LLC tumor-bearing mice preconditioned with IgG or anti-CSF1R antibody and treated
with vehicle or glufosinate (20 mg/kg).
Data information: In each histological quantification, n represents the number of animals. Six images per lung were analyzed. Scale bars: 2 mm. Data are reported as
means  SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Exact P values and statistical tests are reported for each experiment in Appendix Table S2.
Source data are available online for this figure.
▸Figure 6. Glufosinate treatment promotes M1-like TAMs, CTL tumor accumulation, vessel pruning, and normalization and inhibits metastasis in a murinemodel of melanoma.
A Experimental plan. Mice were intradermally injected with YUMM 1.7 (CD90.1+) cells. When the tumor reached 80–100 mm3 size, mice were treated by gavage with
glufosinate (20 mg/kg) or vehicle for 14 days.
B, C Intradermal YUMM 1.7 (CD90.1+) tumor growth over the time (B) and number of metastatic lesions per lung (C) in vehicle and glufosinate (20 mg/kg)-treated mice
(pool of 2 independent experiments; 10 mice per condition in total).
D Representative images of metastatic lesions checked by DAB-H stain for CD90.1 positivity in vehicle and glufosinate (20 mg/kg)-treated mice (n = 6). Six images per
lung were analyzed. Scale bar: 2 mm. Zoomed area scale bar: 50 lm.
E, F FACS quantification of M1-like MHC class IIhigh (E) and MHC class IIlow (F) CD11c+ CD206 TAMs over the total number of F4/80+ cells in vehicle and glufosinate
(20 mg/kg)-treated mice (n = 6).
G Quantification and representative images of CD11c+ cells over the total number of F4/80+ cells in vehicle and glufosinate (20 mg/kg)-treated mice (n = 6). Six
images per tumor were analyzed. Scale bars: 50 lm.
H, I FACS quantification of M2-like MHC class IIhigh (H) and MHC class IIlow (I) CD11c CD206+ TAMs over the total number of F4/80+ cells in vehicle and glufosinate
(20 mg/kg)-treated mice (n = 6).
J Quantification and representative images of CD206+ cells over the total number of F4/80+ cells in vehicle and glufosinate (20 mg/kg)-treated mice (n = 6). Six
images per tumor were analyzed. Scale bars: 50 lm.
K, L FACS quantification of M1-like MHC class IIhigh (K) and M2-like MHC class IIlow (L) TAMs over the total number of F4/80+ cells in vehicle and glufosinate (20 mg/
kg)-treated mice (n = 6).
M Quantification of MHC-II protein, expressed as mean fluorescence intensity (MFI), on F4/80+ cells, was obtained by flow cytometry (n = 6).
N RT–PCR quantification of M2 (Arg1 and Cxcr4) and M1 (Cxcl9 and Nos2) markers in vehicle and glufosinate (20 mg/kg)-treated mice (n = 6).
Data information: Data are reported as means  SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Exact P values and statistical tests are reported for each
experiment in Appendix Table S2.
Source data are available online for this figure.
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syngenic marker CD90.1 (Fig 6A). In line with the LLC model,
glufosinate did not affect either the average tumor volume (Fig 6B)
or tumor weight (Fig EV4A). Body weights were comparable as well
(Fig EV4B). We then checked the presence of lung metastatic foci,
and we found a significant reduction of metastatic lesions in glufosi-
nate-treated mice compared to the vehicle group (Fig 6C and D).
Also in this model, we evaluated the features of the F4/80+ TAM
infiltrate by FACS and histological analysis for the M1 markers
CD11c or MHCII and the M2 marker CD206 (MRC1) (Pucci et al,
2009; Andreu et al, 2010; Movahedi et al, 2010; Rolny et al, 2011;
Laoui et al, 2014; Wenes et al, 2016). The overall F4/80+ macro-
phage abundance in the tumors was comparable in both groups
(Fig EV4C and D). However, in tumors treated with glufosinate we
found an increase of M1-like macrophages (Fig 6E–G) and a reduc-
tion of M2-like TAMs as confirmed by both FACS and histological
analysis (Fig 6H–J). Glufosinate also enlarged the fraction of TAMs
displaying high antigen presentation potential as shown by the
increased percentage of MHCIIhi cells (Fig 6K and L) and augmented
MHCII expression per cell (Fig 6M). qPCR experiments on mRNA
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expression was decreased, whereas Cxcl9 and Nos2 were increased
in response to glufosinate treatment in vivo (Fig 6N).
In line with the results in LLC tumors, glufosinate decreased
both tumor blood vessel length (Fig 7A) and area (Fig 7B) in
YUMM tumors as well. Tumor vessels in glufosinate-treated mice
displayed increased vascular coverage as indicated by an increased
percentage of a-SMA+ peri-vascular area (Fig 7C). This associated
with reduced tumor hypoxia, assessed by staining for CA9 upon
glufosinate treatment (Fig 7D), altogether suggesting increase
blood vessel functionality.
To confirm that GS inhibition counteracts the immunosuppres-
sive phenotype of macrophages, we quantified by FACS intratumoral
T cells as a readout. Since the effects of glufosinate on CD4+ T cells
in the LLC model were negligible, we focused on CD8+ T cells, to
find that CD8+ T-cell infiltration and activation were significantly
increased in glufosinate-treated versus untreated mice (Fig 7E and
F). These data demonstrate that glufosinate treatment in a skin
cancer model reduces the size of metastatic lesions by hindering the
immunosuppressive and pro-metastatic potential of TAMs.
In BALB/c mice, the highest well-tolerated dose of glufosinate
was 10 mg/kg. We then assessed if 4T1 triple-negative breast
tumors, orthotopically implanted in the mammary fat pad, were
sensitive at this dose of glufosinate (Fig 8A). Also, in this cancer
model, glufosinate did not reduce tumor volumes (Fig 8B) and did
not induce weight loss in mice (Fig 8C). However, we found a
significant reduction of metastatic nodules (Fig 8D) and total meta-
static area (Fig 8E) in glufosinate-treated mice compared to vehicle
group. Furthermore, glufosinate significantly increased the inci-
dence of metastatic lesions smaller than 0.5 mm2 and reduced the
incidence of those bigger than 1.0 mm2 (Fig 8F and G). At the meta-
static foci, glufosinate treatment did not induce any change in the
total F4/80+ MAM infiltration (Fig 8H); however, upon treatment,
MAMs were mainly CD206low (Fig 8I).
To measure the effects of glufosinate on cancer cell intravasation,
the amount of circulating cancer cells was evaluated, at the time of
tumor resection, in the blood of mice orthotopically injected with
4T1-GFP+ (Fig 8J). Glufosinate reduced the amount of GFP+ cells
(Fig 8K). Outgrown GFP-labeled CTC colonies from cultured freshly
drawn blood were significantly reduced by glufosinate (Fig 8L). In
neoadjuvant therapeutic regimen, glufosinate improved the survival
of post-surgical mice (Fig 8M).
To assess the effects of glufosinate on the extravasation of circu-
lating tumor cells (CTCs) and their seeding at the metastatic site,
after a 2-day preconditioning with glufosinate treatment of the host
mice, 4T1-GFP+ cells were injected by tail vein to mimic the
progression of metastases unrespective of the primary tumor
(Fig 8N). Mice were sacrificed after 48 h of treatment, and the lungs
were analyzed by qPCR. Glufosinate reduced GFP expression in
lungs (Fig 8O). Altogether, glufosinate is able to impair both cancer




Figure 7. Glufosinate treatment promotes CTL tumor accumulation, vessel pruning, and normalization in a murine model of melanoma.
A–C Quantification of total length of vessels (A), of CD31+ tumor vessel area (B), and of aSMA+ pericyte-covered vessels over the total number of CD31+ vessels (with
representative images) (C) in vehicle and glufosinate (20 mg/kg)-treated mice (n = 6). Six images per tumor were analyzed. Scale bar: 50 lm.
D Quantification and representative images of CA9+ tumor hypoxic areas in vehicle and glufosinate (20 mg/kg)-treated mice (n = 6). Six images per tumor were
analyzed. Scale bar: 50 lm.
E, F FACS quantification of CD8+ cytotoxic T cells (E) and CD69+ CD8+ T cells (F) over the total number of CD45+ in vehicle or glufosinate (20 mg/kg)-treated mice
(n = 6).
Data information: Data are reported as means  SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Exact P values and statistical tests are reported for each
experiment in Appendix Table S2.
Source data are available online for this figure.
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Glufosinate distributes in tissues but does not induce liver or
brain toxicity
Having established that glufosinate produces a significant effect in
different cancer-bearing mice with respect to angiogenesis, immune
suppression, and metastasis formation, we needed to assess the
amount of the molecule actually found in non-malignant tissues,
together with the evaluation of the main hematological parameters
as well as brain and liver functions.
Treatment with glufosinate did not induce neither weight loss in
mice (Fig 9A) nor it modified blood counts (Fig 9B). Although liver
accumulation of glufosinate was significant in treated versus
untreated mice, with the highest amount of glufosinate detected
when the 20 mg/kg dose was administered (Fig 9C), the blood indi-
cators of liver function were unchanged (Fig 9D), suggesting the
glufosinate is not hepatotoxic at the used concentrations. Finally,
glufosinate in the brain was mildly accumulating though its concen-
tration was higher, though not significantly, at 20 mg/kg versus
10 mg/kg (Fig 9E). We speculate that this low but dose-dependent
accumulation is due to the presence of glufosinate in the blood-
stream of the brain favoring the idea that glufosinate has not high
propensity to cross the blood–brain barrier (Kishore & Shah, 1988).
This idea was further corroborated when performing brain toxicity
assays with respect to both sensory neurons and motoneurons. To
this end, we measured the grip strength (Fig 9F and G) and the
latency to fall off an accelerating rotarod (Fig 9H) in vehicle and
glufosinate-treated mice before the treatment (baseline), after 1 day
(acute toxicity) and after 15 days (chronic toxicity). Glufosinate
treatment did not alter the mean paw withdrawal force measured by
the von Frey test, excluding the presence of tactile allodynia (Fig 9I
and J). All together, these results demonstrate that glufosinate treat-
ment accumulates not only in pathological tissues but also in the
normal tissues, it barely crosses the blood–brain barrier and it does
not induce liver and moto/sensory neuron toxicity as well as blood
count defects.
Discussion
A tumor consists not only on transformed cells, but also on stromal
cells that can be recruited and hijacked by cancer cells. It follows
that the interactive mechanisms between different cells within the
tumor, that define the so-called tumor microenvironment (TME),
are also very complex and importantly contribute to tumor malig-
nancy (Binnewies et al, 2018). An important stromal component in
the TME is represented by TAMs (Mazzone et al, 2018; Prenen &
Mazzone, 2019). TAMs take part to several steps in the formation of
metastasis (Pollard, 2004; Komohara et al, 2016). In particular,
these cells help cancer cells evading the immune system and
promote angiogenesis. Additionally, the presence of macrophages at
the pre-metastatic niche supports a role for these cells in preparing
the metastatic niche for the arrival of newly disseminated cancer
cells or in favoring cancer cell survival in a site different from the
primary tumor (Nielsen & Schmid, 2017). During these different
steps, cancer cells adapt their metabolism to increase energy
production to proliferate or to allow survival (Renner et al, 2017).
In doing so, these cells modify the metabolic composition of the
TME, inducing the recruitment of macrophages through mecha-
nisms that can be mediated by functionally relevant metabolic
reprogramming. Identification of the metabolic checkpoints regulat-
ing macrophagic function, which can be targeted to improve cancer
specific immune responses, is now a promising strategy for thera-
peutical intervention (Mazzone et al, 2018). We have recently iden-
tified GS as an enzyme playing a fundamental role in the acquisition
of the protumoral and pro-metastatic function of TAMs (Palmieri
et al, 2017b). These results were achieved by pharmacological GS
inhibition in vitro and by genetic GS ablation specifically in macro-
phages in a single murine model of cancer (Palmieri et al, 2017b).
However, the efficacy of in vivo pharmacological targeting of GS in
several tumor model has never been proven so far.
Here we present data on the pharmacological inhibition of GS in
lung, breast, and skin murine models of metastatic cancer by using
◀ Figure 8. Glufosinate treatment inhibits metastasis in a murine model of breast cancer.A Experimental plan. Mice were injected with 4T1 cells in the mammary fat pad. When the tumor reached 80–100 mm3 size, mice were treated by gavage with
glufosinate (10 mg/kg) or vehicle for 14 days.
B–D Evaluation of 4T1 tumor growth over the time (B), mice body weight (C), and number of metastatic nodules (D), in vehicle and glufosinate (10 mg/kg)-treated mice
(pool of 2 independent experiments; 10 mice per condition in total).
E–G Total metastatic area (E) and number of lung metastatic lesions per size by H&E staining (F) with representative images (G) in vehicle and glufosinate (10 mg/kg)-
treated mice (n = 8). Six images per lung were analyzed. Scale bar: 2 mm.
H, I Quantification of F4/80+ macrophage density (H), of F4/80+ CD206+ cells infiltration in the lung metastasis and representative images (I), in vehicle and
glufosinate-treated mice (n = 6). Six images per lung were analyzed. Scale bar: 20 lm.
J Experimental plan for intravasation setting. Mice were injected with 4T1-GFP+ cells in the mammary fat pad and immediately treated by gavage with glufosinate
(10 mg/kg) or vehicle for 14 days (neoadjuvant therapeutic regimen). After 14 days of treatment, at the time of tumor resection, blood was collected and analyzed
for GFP+ circulating tumor cells (CTCs). Survival studies were performed until the natural death of the post-surgical mice.
K–M GFP+ CTCs amount in blood, expressed as GFP expression levels, was determined by qPCR (n = 8) (K). Blood was drawn from treated and untreated tumor-bearing
mice at the time of tumor resection and plated in culture dishes. The formation of tumor cell colonies was traced over time. Graph shows the number of GFP+
tumor cell colonies (n = 8) (L). After treatment and tumor resection, overall survival studies were performed until the natural death of the post-surgical mice
(n = 11) (M).
N Experimental plan for extravasation setting. GFP-expressing 4T1 were injected intravenously into BALB/c mice preconditioned with glufosinate (10 mg/kg) or
vehicle for 2 days. After 2 days of treatment, the overall lung metastatic breast cancer cell burden was determined.
O GFP+ cancer cells amount in lungs, expressed as GFP expression levels, was determined by qPCR in vehicle and glufosinate (10 mg/kg)-treated mice (n = 8). The
results were normalized to the vehicle group.
Data information: Data are reported as means  SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Exact P values and statistical tests are reported for each
experiment in Appendix Table S2.
Source data are available online for this figure.
14 of 24 EMBO Molecular Medicine 12: e11210 | 2020 ª 2020 The Authors
EMBO Molecular Medicine Alessio Menga et al
glufosinate, a known inhibitor of plant GS (Occhipinti et al, 2010).
Glufosinate treatment in vitro, as low as 10 lM, recapitulates the
effect of MSO on IL10 macrophages, leading to a metabolic repro-
gramming, associated with a HIF1a-dependent M1-like phenotype,
that functionally translates into a decreased immune suppression,
angiogenesis, and cancer cell invasion.
Our findings that GS-inhibited macrophages counter T-cell
immunosuppression by engaging HIF1a seem in sharp contrast with
the protumoral, immunosuppressive role of HIF1a in hypoxic TAMs
(Doedens et al, 2010). We show that GS inhibition maintains mTOR
active even in hypoxic conditions. This occurs through downregula-
tion of REDD1, a known negative regulator of mTOR in hypoxia.
Active mTOR in hypoxia shields macrophages from the immunosup-
pressive function dictated by hypoxia, forcing macrophages
to display the classical functional program of normoxic
pro-inflammatory M1-like macrophages, wherein mTOR is
A
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Figure 9. Glufosinate treatment does not display blood, liver and neuronal toxicity.
A Time course evaluation of murine body weight during treatment in vehicle and glufosinate (10 and 20 mg/kg)-treated mice (pool of 2 independent experiments; 10
mice per condition in total).
B Blood counts of WBC and RBC in vehicle and glufosinate (10 and 20 mg/kg)-treated mice (n = 8).
C, D Evaluation of liver toxicity following glufosinate treatment. Quantification of liver glufosinate (C) and of hepatotoxicity markers ALT (alanine aminotransferase) and
AST (aspartate aminotransferase) (D) in serum of vehicle and glufosinate (10 and 20 mg/kg)-treated mice (n = 8).
E–J Evaluation of neuronal toxicity following glufosinate treatment. Quantification of brain glufosinate (E), of the grip strength for front paws (triangular bar) (F), for all
paws (rectangle grid) (G), of the latency to fall off an accelerating rotarod (H), and of the mean paw withdrawal force that caused animals’ response in the von Frey
test (left hindpaw, (I); right hindpaw, (J)) as an indicator of the development of tactile allodynia in vehicle and glufosinate-treated mice (n = 4), before the
treatment (baseline), after 1 day (acute toxicity), and after 15 days (chronic toxicity) (pool of 2 independent experiments; 10 mice per condition in total).
Data information: Data are reported as means  SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Exact P values and statistical tests are reported for each
experiment in Appendix Table S2.
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physiologically active. Concomitant activation of HIF1a and mTOR,
and in particular TORC1 (Covarrubias et al, 2015), is responsible for
the acquisition of an immunostimulatory and antitumoral macro-
phage phenotype. Our results clearly demonstrate that hypoxic
TAMs can engage in a pseudo-normoxic state, which is triggered by
GS inhibition.
Our in vitro data are confirmed in several mouse models of
cancer, in which glufosinate treatment significantly reduces metasta-
sis formation and promotes a phenotype switch of TAMs toward a
M1-like state, similarly to what observed in the conditional, macro-
phage-specific, GS knockout mouse (Palmieri et al, 2017b). Since
glufosinate might reach all the cells of the TME, it cannot be ruled
out that stromal cellular components other than TAMs might contri-
bute to the antimetastatic effect displayed by glufosinate. Indeed
genetic targeting of GS in cancer-associated fibroblasts (CAFs) in a
murine model of ovarian cancer induces tumor regression (Yang
et al, 2016). Additionally, GS inhibition in endothelial cells might
impair vessel sprouting during vascular development (Eelen et al,
2018). However, TAM depletion in glufosinate-treated tumor-
bearing mice completely prevents the antimetastatic effect of GS
inhibition, arguing that the drop in metastatic burden in glufosinate-
treated tumor-bearing mice is greatly due to the revert of the
immunosuppressive and proangiogenic function of TAMs. Yet, the
anti-angiogenic effect of glufosinate remains unaltered even upon
TAM depletion, suggesting an endothelial cell autonomous mecha-
nism of inhibition (that is macrophage-independent) of glufosinate
on tumor blood vessel growth (Eelen et al, 2018). The alleged effect
of glufosinate on endothelial cells is sufficient to prune tumor blood
vessels but not to reduce metastasis. This is consistent with previ-
ous findings by our laboratory and others (Shojaei et al, 2007;
Casazza et al, 2012), altogether showing that LLC-derived primary
tumors and metastases are refractory to anti-angiogenic therapies
because of compensatory responses elicited by myeloid cells, which
contribute in several ways to angiogenesis (i.e., by modulating both
endothelial cells and mural cells) and also impose their control on
the adaptive immune system.
The finding, confirmed in several tumor models, that glufosi-
nate-induced rewiring of the TAM phenotype toward an M1-like
state is associated with the inhibition of metastases but not of the
primary tumor points to the involvement of TAMs in the antimeta-
static effect displayed by glufosinate. Indeed, TAMs are known to
affect distant dissemination of cancer cells more than tumor
growth (Qian et al, 2015). TAMs can also promote tumor vascular
abnormalities; therefore, the ability of restoring “tumor vessel
normalization” results in reduced hypoxia and leakage, as well as
increased delivery of therapeutic drugs to the tumor (Mazzone
et al, 2009; Rolny et al, 2011; Leite de Oliveira et al, 2012), and
increased immunosurveillance that can restrain metastatic
outgrowth (Eyles et al, 2010). Based on the effects of glufosinate
in rewiring the TAM phenotype toward a M1-like state, each of
the described mechanisms might conceivably play a role in inhibit-
ing metastatic growth. The additional effect of glufosinate in
increasing tumor vessel perfusion suggests that this drug might be
exploited not only for its immunomodulatory properties, but also
in combination with state-of-the-art anti-cancer drugs (i.e.,
chemotherapy) to enhance their delivery and therapeutic efficacy
against both primary tumor and metastasis. Importantly, macro-
phages patrolling the metastatic niche (namely MAMs, metastasis-
associated macrophages) have been involved in cancer cell
extravasation, angiogenesis, as well as cancer cell survival and
proliferation (Chen et al, 2011; Qian et al, 2011; Nielsen et al,
2016; Celus et al, 2017). By following experimental metastases and
metastatic growth upon primary tumor resection (which mimic
settings of metachronous metastases), we prove that MAMs are
also governed by GS in their M2 phenotype and its inhibition is
favouring a switch toward the M1-like phenotype. This favors the
use of glufosinate in controlling a metastatic relapse. However, we
went beyond these findings, suggesting that glufosinate limits
growth of established metastatic lesions, overall opening the possi-
bility to use this type of therapeutic approach in a curative setting,
following disease relapse or in an adjuvant setting (following the
resection of the primary tumor). From a metabolic point of view,
since MAMs are known to promote metastasis formation through
signaling and metabolic conditioning of the pre-metastatic niche to
prepare the microenvironment for cancer cells survival and prolif-
eration (Qian et al, 2015; Celus et al, 2017; Prenen & Mazzone,
2019), it can be speculated that GS expression in MAMs might be
fundamental to supply glutamine, which is probably a limiting
metabolite in the delicate step of metastatic growth.
Exploitation of targeted therapies against TAMs represents a
promising option to fight cancer. Indeed some clinical efficacy has
been shown by depleting TAMs or by inhibiting their protumoral
functions, for instance, by blocking the CSF1R signaling (Ries et al,
2014). However, general ablation of protumoral macrophage func-
tions or of total macrophages might not represent the correct
strategy due to the possible systemic harmful consequences. Identi-
fication of metabolic checkpoints of macrophage function might
represent a promising strategy to induce selective reprogramming of
abundant protumoral macrophages toward an antitumoral pheno-
type, a process now known a TAM re-education (Beatty et al, 2011;
Rolny et al, 2011; Casazza et al, 2013). Furthermore, new drugs
based on small organic compounds active as enzyme inhibitors,
instead of antibodies, might be available at lower costs. Our results
from glufosinate treatment demonstrate that targeting metabolic
activities crucial for the acquisition of protumoral macrophage
phenotypes is a safe and effective strategy against the immunosup-
pressive function of macrophages.
In conclusion, our data confirm that GS is a metabolic check-
point crucial for the targeting of immunosuppressive and proangio-
genic TAMs, that is ultimately relevant for metastasis formation in
a synchronous setting and in a more clinically relevant metachro-
nous setting. Overall, we show that two different doses of the GS
inhibitor glufosinate do not display overt toxic effects. Our results
clearly point at metabolic immunotherapy as a powerful and feasi-
ble strategy to rewire macrophage function toward an antimeta-
static phenotype, which is currently strongly awaited in the fight
against cancer.
Materials and Methods
Sequence search and analysis
Protein and genomic databases (www.ncbi.nlm.nih.gov) were
screened by using the human GS (accession number NP_
001028216) as a query sequence.
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Construction of expression plasmids
The coding sequence of human GS (accession numbers NM_
001033044.3) was amplified by PCR from human liver cDNA. The
oligonucleotide primers were synthesized corresponding to the
extremities of the coding sequence, with additional BamHI and
HindIII restriction sites as linkers at 50 end allowing unidirectional
cloning. The amplified product was digested (BamHI/HindIII) and
cloned into the pRUN vector for expression in E. coli. The plasmid
containing the coding sequence for human GS (hGS) was trans-
formed into E. coli DH5 cells. Transformants were selected on
2× YT plates containing ampicillin (100 lg/ml) and screened by
direct colony PCR and by restriction digestion of purified
plasmids. The sequence of the insert was verified by DNA
sequencing (StarSEQ).
Bacterial expression and purification of recombinant GS
The expression of recombinant hGS was carried out at 37°C in
E. coli BL21 (DE3) cells. The inclusion bodies were purified on a
sucrose density gradient (Frelin et al, 2012; Zallot et al, 2013) and
washed with TE buffer (10 mM Tris–HCl, 0.1 mM EDTA, pH 7.2).
Reconstitution of functional GS and enzymatic assay
The recombinant hGS was solubilized in a solubilization buffer
containing Urea (2 M), DTE (10 mM), and Tris–HCl (100 mM, pH
9.0) at 25°C under stirring for 3 or 4 h. The insoluble residues were
removed by centrifugation (20,800 g for 10 min at 4°C). The reac-
tion catalyzed by hGS was measured by a microtiter assay using
inorganic phosphate detection (Gawronski & Benson, 2004). The
reaction mix contained 50 mM HEPES (pH 7.2), 50 mM
MgCl26H2O, 20 mM monosodium glutamate, 10 mM NH4Cl, and
purified recombinant hGS.
The final volume of reaction mix was 200 ll. To determine
the amount of produced phosphate, 10 ll of each dilution of the
phosphate standard from 0 to 15 mM was added to reaction mix
instead of the initiation substrate. After 8 min, 50 ll of the reac-
tion mix was added in a 96-well Microwell plate (Nunc,
Roskilde, Denmark) to 150 ll of two part of 12% w/v L-ascorbic
acid in 1N HCl and one part of 2% w/v ammonium molybdate
tetrahydrate in ddH2O, prepared just before use. After 5 min,
150 ll of 2% sodium citrate tribasic dihydrate and 1% acetic
acid in ddH2O was added to the wells to stop color develop-
ment. The reaction was allowed for 5 min at room temperature
before reading the absorbance at 750 nm with a GloMax
Discover Multimode Microplate Reader (Promega). To determine
the apparent kinetic parameters of recombinant hGS, the initial
reaction activity was measured varying the concentrations of a
substrate in the presence of a fixed saturating concentration of
the other substrates. A series of dilutions of glutamate or ATP
was prepared to determine their respective Michaelis–Menten
(half-saturation) constant (Km) of the human recombinant GS
and the Ki values of MSO or glufosinate. The GS biosynthetic
reaction was also performed in presence of different concentra-
tions of MSO or glufosinate. These compounds were
added simultaneously with the other mix components before of
ATP addition.
Protein sequence sampling
GS sequences from H. sapiens (NP_002056.2) and Z. mays
(NP_001105443.2) were collected from the RefSeq protein sequence
database and used as queries to search for homologous sequences
in H. sapiens (taxid:9606) (and other mammalia (taxid:40674)) and
Z. mays (taxid:4577) (and other plant species (taxid:3193)).
Crystal structure sampling via folding recognition
Protein-crystallized structures homologous to GS were searched by
pGenThreader (Lobley et al, 2009) and iTasser (Yang & Zhang,
2015). A previously described method (Trisolini et al, 2019) allowed
sampling 17 crystal structures, that were subsequently aligned and
superimposed to be compared with PyMOL (Ordog, 2008). Residues
within 4 Å from substrates/cofactors crystallized in the sampled
structures were highlighted to compare the related ligand-binding
regions, which were superimposed by using PyMOL as previously
described (Pierri et al, 2010; Bossis et al, 2014; Trisolini et al, 2019).
Multiple sequence analysis
The parameters selected to retain the sampled sequences were E-
values, query coverage, and percentage of identical amino acids and
the threshold was set at E = 1086, query coverage = 60%, and the
percentage of identical amino acids = 50. ClustalW, implemented in
the sequence editor suit Jalview, was used to build a MSA of 36
sequences (10 mammalian, 9 plant, and 17 sequences from the crys-
tallized structures) as previously indicated (Pierri et al, 2010; Bossis
et al, 2014; Trisolini et al, 2019). MatGAT was used to calculate the
amino acid identity or similarity (expressed in %) among the
sequences sampled through the blast and the fold recognition tools
(Campanella et al, 2003).
Cell culture
Human lung carcinoma A549, murine 4T1 (GFP+) mammary carci-
noma, YUMM1.7 (CD90.1+) melanoma, and Lewis lung carcinoma
(CD90.1+) cells, obtained from ATCC, were maintained in DMEM
media containing 25 mM glucose, 4 mM glutamine, 100 U/ml of
penicillin, 100 lg/ml of streptomycin, and 10% fetal calf serum.
Cells were cultured in 5% CO2/95% air at 37°C in a humidified
chamber, split every 2–3 days, passaged at ratios that ranged from
1:4 to 1:8, and used up to passage 10 (Meeth et al, 2016). For tumor
inoculation, cancer cells were harvested at approximately 60–85%
confluence on the day of injection. Cells were trypsinized with
0.25% trypsin for approximately 2–3 min before deactivation
with media containing 10% serum. They were then washed twice
with sterile 1× PBS and counted with a hemocytometer. Cell viabil-
ity was determined after 72 h of incubation, using the CellTiter 96
Non-Radioactive Cell Proliferation Assay (Promega) as described
(Menga et al, 2017; Palmieri et al, 2017b).
Cell isolation and culture
Human monocytes were isolated from human buffy coats with
CD14 MicroBeads (Miltenyi Biotec Inc.) as previously described
(Palmieri et al, 2015, 2017b). After differentiation, macrophages
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were stimulated with LPS/IFNc (for M1 polarization) and IL10 (for
M2 polarization). Experiments of inhibition were performed by
adding 1 mM MSO, or 10, or 20 lM glufosinate one h before the
cytokines for activation. For HIF1a inhibition, cells were stimulated
with LPS/IFNc or IL10 with and/or without a previous 2 h incuba-
tion with glufosinate and 5 lM Acriflavine (ACF). Murine bone
marrow-derived macrophages (BMDMs) were derived from bone
marrow precursors as described before (Palmieri et al, 2017b).
Briefly, bone marrow cells (1.6 × 106 cells/ml) were cultured in
DMEM supplemented with 20% FBS and 30% L929 conditioned
medium as a source of M-CSF. After 3 days of culture, an additional
3 ml of differentiation medium was added. At day 7, macrophages
were pretreated with glufosinate, polarized with 10 ng/ml IL10 or
with 100 ng/ml LPS plus 20 ng/ml IFNc for 24 h, and finally
harvested with ice-cold Ca2+ and Mg2+-free PBS. For the nutrient-
sensitive mTOR complex 1 (mTORC1) inhibition, BMDMs were
stimulated with IL10 with or without a previous 2 h incubation with
glufosinate and/or 20 nM rapamycin (Rapa) (Byles et al, 2013) in
normoxic and hypoxic conditions.
RNA and protein expression analysis
Total RNA was extracted from cells and reverse transcribed ad
described (Iacobazzi et al, 2009; Palmieri et al, 2017a,b). TaqMan
probes were purchased from IDT and Thermo Fisher. Analysis was
carried out with a QuantStudio real-time PCR system (Thermo
Fisher). All transcript levels were normalized against the b-actin
expression level.
For Western blotting analysis, whole cell lysates were prepared
by treating pelleted cells with ice-cold RIPA buffer (1% Nonidet P-
40, 50 mM Tris–HCl pH 7.4, 150 mM NaCl, 0.1% SDS, 2 mM EDTA,
0.5% sodium deoxycholate) containing 1 × protease inhibitors
(Sigma P8340) and 1 mM PMSF (Sigma P7626) for 30 min at 4°C
(Palmieri et al, 2017a). Proteins were analyzed by SDS–PAGE TGX
Stain-FreeTM Fast-CastTM (Bio-Rad) and visualized by ChemiDocTM
MP System (Bio-Rad) or with Coomassie Blue dye (Lauderback
et al, 2003; Palmieri et al, 2014, 2017b). In the case of GS, N-term-
inal sequencing was carried out as described previously (Todisco
et al, 2006, 2014). The amount of purified GS was estimated by
laser densitometry of stained samples, using bovine albumin as
protein standard. Proteins were electroblotted with iBlot Transfer
System (Life Technologies) and subsequently treated with the dif-
ferent antibodies as follows: anti-GS (Sigma MAB302) (Palmieri
et al, 2014), anti-phospho-4E-BP1 (Cell Signalling, 2855), anti-
4E-BP1 (Cell Signalling, 4923), anti-p70 S6 Kinase (Cell Signalling,
9202), anti-phospho-p70 S6 Kinase (Cell Signalling, 9206), anti-
REDD1 (Santa Cruz, sc-46034), anti-S6 (Cell Signalling, 2217), anti-
phospho-S6 (Cell Signalling, 4858) (Wenes et al, 2016; DiConza
et al, 2017), CCL18 (Novus, NBP1-79940), TNFa (Abcam, ab9635),
and vinculin (Sigma V9131-.2ML), which was used as housekeeping
gene. The immunoreaction was detected by the ECL plus system
(Amersham). More details about reagents and dilutions are reported
in Appendix Table S1.
Mass spectrometry analysis
For mass spectrometry analysis, cells were scraped in 80%
methanol to extract polar metabolites, which was subsequently
centrifuged and dried using a vacuum concentrator (Palmieri et al,
2014, 2017a). For plasma extraction, 20 ll of medium was added to
methanol and treated as above. The dried metabolite samples were
stored at 80°C. For glufosinate quantification in brain, liver, and
tumor, 20 mg of frozen tissues were ground to a fine powder by
metal beads in a cryogenic homogenizer and extracted with acetoni-
trile-methanol-KH2PO4 (50:30:20) buffer. Measurements of metabo-
lites (Zallot et al, 2013; Palmieri et al, 2014, 2017b) and glufosinate
(Wang et al, 2008) were obtained with an Acquity UPLC system
interfaced with a Quattro Premier mass spectrometer (Waters).
Tumor grafts
For animal studies, a “single-blind” design was used. 1 × 106 Lewis
lung carcinoma (CD90.1+) cells and YUMM1.7 (CD90.1+) melanoma
cells were injected subcutaneously and intradermally, respectively,
into a shaved rear flank of 8-week-old C57BL/6 mice, whereas 1 × 106
4T1 (GFP+) mammary carcinoma cells, suspended in 200 ll PBS,
were orthotopically inoculated to the mammary fat pad of 8-week-old
BALB/c mice. Following tumor growth, mice randomization was
performed to reach same tumor average per cage and normalize the
pharmacological effects on metastasis. Tumor volumes were measured
three times a week with a caliper and calculated using the formula:
V = p × (d2 × D)/6, where d is the minor tumor axis and D is the
major tumor axis. Glufosinate solution was prepared in sterile water
for injection and administered directly into the stomach of mice twice
a day via oral gavage. Tumor-bearing mice received glufosinate until
end stage, after tumors reached volume of 80–100 mm3. At the end
stage, tumor weight was measured and tumors, lungs, and other
organs were collected for histological examination. In adjuvant thera-
peutic regimen setting, LLC-bearing mice received glufosinate treat-
ment 14 days after tumors reached volume of 400 mm3 and were
resected. The post-surgical mice were sacrificed at end stage, and the
lung metastases were analyzed.
Extravasation assay
GFP-expressing 4T1 subclones (1 × 106 cells) were injected intra-
venously into 9-week-old BALB/c female mice preconditioned with
glufosinate for 2 days. After 2 days of treatment, to determine the
overall lung metastatic breast cancer cell burden, genomic DNA was
purified from the contralateral lung, subjected to quantitative real-
time PCR (qPCR) using specific primers for GFP (Forward:
CATGGTCCTGCTGGAGTTCGTG; Reverse: CGTCGCCGTCCAGCTC
GACCAG; BD Biosciences) and the results were normalized to the
vehicle group.
Neoadjuvant therapeutic regimen, intravasation, and
survival assay
1 × 106 GFP-labeled 4T1 cells were injected in the mammary fat pad
of 9-week-old BALB/c female mice. After 14 days of treatment, at
the time of tumor resection, blood was collected (300 ll) by retro-
orbital bleeding and subjected to hemolysis. Genomic DNA was
purified and subjected to quantitative real-time PCR (qPCR) using
specific primers for GFP (as above), and the results were normalized
to the vehicle group. Survival studies were performed until the natu-
ral death of the post-surgical mice.
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Metastasis analysis
Lung metastasis nodules were contrasted after intratracheal injec-
tion of 15% India ink solution and assessed under a stereomicro-
scope. Where indicated, the lungs were embedded in paraffin,
sectioned, and stained with Hematoxylin and eosin (H&E) to check
metastatic lesion area. The lung metastatic lesions originated from
primary melanoma were checked by DAB-H stain for CD90.1 posi-
tivity. The area of lung metastasis was measured using ImageJ soft-
ware (Bethesda, MD, USA).
FACS analysis and flow sorting of tissue- and
tumor-associated macrophages
LLC or YUMM tumor-bearing mice were sacrificed by cervical dislo-
cation, and tumors were harvested. Tumors or other organs were
minced in RPMI medium containing 0.1% collagenase type I and
0.2% dispase type I and incubated in the same solution for 30 min
at 37°C. Samples from spleen were mechanically dissociated. The
digested or dissociated tissues were filtered using a 70 lm pore
sized mesh, and cells were centrifuged 5 min at 1,200 g. Red blood
cell lysis was performed by using Hybri-MaxTM (Sigma-Aldrich).
For flow sorting, the myeloid cell population in the tumor single cell
suspension, and when appropriate in flushed splenocytes, was
enriched with CD11b-conjugated magnetic beads (MACS, Miltenyi
Biotec) and separated through magnetic columns (MACS, Miltenyi
Biotec). Cells were resuspended in FACS buffer (PBS containing 2%
FBS and 2 mM EDTA) and incubated for 15 min with Mouse BD Fc
BlockTM purified anti-mouse CD16/CD32 mAb (BD Biosciences,
553142) and stained with the following antibodies for 30 min at 4°C
in dark: anti-CD4 (BioLegend,100540), anti-CD8 (eBioscience, 53-
0081-82), anti-MHCII (eBioscience, 46-5321-82), anti-CD206 (BioLe-
gend, 321120), anti-CD11c (eBioscience, 17-0114-81), anti-CD69
(BioLegend,104522), anti-41BB (Thermo Fisher Scientific, 25-1371-
80), anti-CD45 (BioLegend, 103108), anti-F4/80 (BioLegend,
123128), anti-TCRbeta (Thermo Fisher Scientific, 17-5796-82), anti-
CD25 (eBioscience, 25-0251-82). Cells were subsequently washed
and resuspended in cold FACS buffer before FACS analysis or flow
sorting by a FACS Verse or FACS Aria (BD Biosciences), respec-
tively. Suitable negative isotype controls were used to rule out the
background fluorescence for the used fluorochromes (FITC, PE, PE-
Cy5, PE-Cy7, and APC). To ensure that analyses were made only of
viable cells and not debris, all events labeled with 7AAD were
excluded. Percentage of each positive population and mean fluores-
cence intensity (MFI) were determined using quadrant statistics.
More details about reagents and dilutions are reported in
Appendix Table S1.
Immunostainings
For serial sections cut at 7 lm thickness, tissue samples were fixed
in 2% PFA overnight at 4°C, dehydrated, and embedded in paraffin.
Paraffin slides were first rehydrated to further proceed with antigen
retrieval in citrate solution (DAKO). The sections were blocked with
the appropriate serum (DAKO) and incubated overnight with the
following antibody: rat anti-CD31 (BD, 557355) 1:200, rat anti-F4/
80 (Bio-Rad, MCA497G) 1:100, rabbit anti-hypoxyprobe (NPS, HP3-
100KIT) 1:100, rat anti-Thy1.1 (Abcam, ab85352) 1:200, rat anti-
actin a-smooth muscle (Sigma-Aldrich, C6198-.2ML) 1:500, goat
anti-CD206 (R&D Systems, AF2535) 1:100, rabbit anti-CA9 (Novus
Biologicals, NB100-417) 1:100, rabbit anti-FITC (Bio-Rad, 4510-
7604) 1:100, hamster anti-CD11c (eBioscience, 14-0114-81) 1:200.
Appropriate secondary antibodies were used: Alexa 488 (Invitrogen,
A11001)-, 647 (Invitrogen, A21447)-, or 568 (Invitrogen, A11057)-
conjugated secondary antibodies 1:200, biotin-labeled antibodies
(bio-connect: 711-065-152 and 705-065-003) 1:300 and, when neces-
sary, TCA fluoricine or TSA Plus Cyanine 3 System amplification
(Perkin Elmer, Life Sciences) were performed according to the
manufacturer’s instructions. Whenever sections were stained in flu-
orescence or IHC, ProLong Gold mounting medium with or without
DAPI (Invitrogen) and DPX mounting were used, respectively.
Microscopic analysis was done with an Olympus BX41 microscope
and cellSens imaging software. More details about reagents and
dilutions are reported in Appendix Table S1.
Mice blood analysis
Whole blood from the retro-orbital sinus was collected into EDTA-
treated tubes and used for red and white blood cell counting by CBC
disposable hemacytometer. For plasma analysis, cells were removed
from plasma by centrifugation for 15 min at 2,000 g using a refriger-
ated centrifuge. The resulting supernatant designated plasma was
used for glutamine quantification by mass spectrometry. For serum
analysis, whole blood as above was collected into untreated tubes.
After collection, whole blood was left undisturbed 30 min at room
temperature to allow the clot. The clot was removed by centrifuging
at 2,000 g for 10 min in a refrigerated centrifuge. The resulting
supernatant designated serum was used for hepatic enzymes
levels quantification.
Ex vivo culture of CTCs
A cardiac puncture was executed to harvest arterial blood that was
kept on ice in lithium heparin Microtainer Tubes (BD Biosciences).
100 ll of blood was seeded in a 10-cm culture dish in 10 ml DMEM
plus 10% FCS and 1% penicillin-streptomycin. After 14 days of
culture, cancer cell colonies were evaluated under a fluorescence
microscope. The total number of colonies was quantified manually
in 2 or more petri dishes for each animal on an Olympus IX71
microscope (La Porta et al, 2018).
Tumor homogenates
For the preparation of whole tumor lysates, 20 mg of frozen mouse
tumors was ground to a fine powder by sand beads and homogenized
in 500 ll of extraction buffer (10 mM Tris, pH 7.6, 5 mM EDTA,
50 mM NaCl, and 1% Triton X-100) with protease inhibitor cocktail
(set I, Calbiochem) and phosphatase inhibitor cocktail (set I and II,
Sigma). The homogenates were centrifuged at 12,000 g for 20 min at
4C, and the supernatants were used for Western blotting analysis.
Tumor interstitial fluid
Tumor interstitial fluids were collected by centrifugation method as
reported (Wiig et al, 2003), and the secreted IFN-c was quantified
by ELISA (Abcam, ab46081).
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Cancer cell invasion assay
The upper side of a Transwell chamber with a 8.0 lm-porous poly-
carbonate membrane filter (Costar) was coated with 5 lg
Matrigel (Matrix Growth Factor Reduced from Corning). M2
macrophages pretreated or not with MSO/glufosinate were
washed, detached in cold PBS, and then added (5 × 104/well)
together with calcein-labeled A549 or LLC cells (1 × 105/well) to
the upper chamber in RPMI medium supplemented with 2% FBS.
RPMI medium supplemented with 10% FBS was added to the
lower well to create a gradient of serum as chemoattractant stimu-
lus. The migration of A549 or LLC cells was assayed after 24 h of
incubation. At this time point, the membranes were removed and
stained with DAPI, and the number of cells that had invaded the
lower chamber was counted in three randomly selected fields
under a fluorescence microscopy.
Cancer cell proliferation
Murine BMDMs pretreated or not with glufosinate and polarized
into M2 macrophages were washed in PBS and added (5 × 104/well)
in glutamine-free medium to the upper side of a Transwell chamber
with a 0.4 lm-porous polycarbonate membrane filter (Costar).
Murine LLC cells (1 × 105/well) were added to the lower chamber
in glutamine-free medium, and after 72 h of incubation, the cell
number was measured spectrophotometrically by using cell count-
ing kit-8 (Dojindo) at 450 nm.
Effects of glufosinate on cancer cells proliferation, migration,
and viability
Murine cancer cells (1 × 105/well) were treated directly with glufos-
inate in normal and glutamine-free medium and monitored for 72 h
by using the CellTiter 96 Non-Radioactive Cell Proliferation Assay
(Promega) as described in (Menga et al, 2017; Palmieri et al,
2017b). The migration of glufosinate-treated cancer cells was evalu-
ated in normal and glutamine-free medium as described before, but
without macrophages.
Endothelial cell capillary formation
2 × 105 M2 polarized, human macrophages, pretreated or not with
MSO/glufosinate, were washed in PBS and embedded in Matrigel
(BD biosciences). After 4 h, 1 × 104 Human Umbilical Vein
Endothelial Cells (HUVEC) were added for an additional 4 h to the
Matrigel. HUVEC capillary network was measured by counting the
number and length of branches using ImageJ software.
Blood vessel perfusion and hypoxia assessment
Tumor-bearing mice were injected intravenously with 0.05 mg fluo-
rescein isothiocyanate (FITC)-conjugated lectin (Lycopersicon escu-
lentum; Vector Laboratories) and perfused (lectin+) tumor vessels
were counted on tumor sections. Tumor-bearing mice were injected
i.p. with 60 mg/kg pimonidazole hydrochloride and tumor hypoxic
(pimonidazole+) areas were evaluated on paraffin sections
immunostained with the Hypoxyprobe-1-Mab1 (Hypoxyprobe kit,
Chemicon) following the manufacturer’s instructions.
T-cell purification and expansion
CD8+ T cells were isolated by negative selection using CD8+ T Cell
Isolation Kit (Miltenyi). Fresh cells after isolation were then washed
with PBS and resuspended in RPMI 1640 medium supplemented
with 10% FCS, 10 mM HEPES, 2 mM glutamine, and non-essential
amino acids. Purity of cells was checked by flow cytometric analysis
and cell population with > 90% purity was taken. These cells were
activated and expanded. To address the immunopromoting function
of macrophages, cultured primary IL10-polarized macrophages, with
or without a previous 2-h incubation with glufosinate/MSO and/or
rapamycin, were seeded in 96-well plates (2 × 105/ml) and cocul-
tured with CD8+ T cells in stimulator–responder ratios of 1:2.
Macrophage stimulants and treatments were washed away exten-
sively before adding T-cell suspensions in a final volume of 200 ll.
Cells were cocultured for 5 days in the presence of anti-CD3/CD28
Dynabeads (Life Technologies) and IL-2 25 U/ml for activation
(Palmieri et al, 2017b). As controls, 1 × 105 CD8+ T cells/well were
also plated without macrophages and left alone throughout the
entire procedure. T cells were collected after 5 d in culture, and after
incubation with 1 lCi/well tritiated thymidine, their proliferation
was evaluated by reading radioactivity as cpm (counts per minute).
Proliferation measured in T cells without macrophages was set at
100%. Where indicated, cocultures of macrophages and CD8+ T
cells were kept in normoxia or hypoxia (1% oxygen) throughout the
entire procedure.
T-cell migration assay
Migration of CD8+ T cells was evaluated by using a Transwell
Permeable system with 5-lm polycarbonate membrane (Costar). To
determine cell migration in response to soluble factors secreted by
macrophages, the last were precultured in the lower chamber for
7 days in RPMI 10% FBS and then activated for 8 h with LPS/IFNc
or IL10 with or without MSO/glufosinate. Then, the medium was
changed, and after 18 h, autologous CD8+ T cells at 48 h culture
after isolation in the presence of anti CD3 (1 lg/ml) and anti CD28
(1 lg/ml) were placed in the upper chamber (2 × 105 cells in 70 ll
of medium with 10% FBS). After a 3 h incubation of macrophages
with CD8+ T cells, the amount of migrated T cells was evaluated by
microscopy (Finisguerra et al, 2015).
Moto-neuron toxicity assays
To evaluate the mouse forearm grip strength, measured in Newtons
(N), a grip strength meter (Columbus Instruments, OH, USA) was
employed. Mice held by the tail were allowed to grip the trapeze
with their front paws and then pulled with their body parallel to the
floor. Each animal was evaluated 15 times in sets of 3 with resting
intervals. Neuromuscular strength was assessed in vehicle and
glufosinate-treated mice, before the treatment (baseline), after 1 day
(Acute Toxicity), and after 15 days (Chronic Toxicity). After exclud-
ing the highest and lowest values, the remaining readings for each
mouse were averaged.(Fujii et al, 2019). In a different setting, a
special grid allowing the mouse to grasp it with all four limbs was
used. In this case, all-animal strength is measured. Furthermore,
mice were trained daily for 3 consecutive days on the rotarod appa-
ratus (Rotarod apparatus, May Commat RR0711, Ankara, Turkey;
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rod diameter: 2 cm) at a constant speed of 18 rotations per minute
(rpm) (Salat et al, 2015). After 24 h training, the inability to remain
on the rotating rod for 300 s (indication of motor impairment) was
measured in vehicle and glufosinate-treated mice, before the treat-
ment (baseline), after 1 day (Acute Toxicity), and after 15 days
(Chronic Toxicity). Then, the von Frey test was performed to evalu-
ate a painful response to an harmless stimulus (tactile allodynia) by
using an electronic von Frey unit (Bioseb, Montpellier, France)
supplied with a single flexible filament applying increasing force
(from 0 to 10 g) against the plantar surface of the hind paw of the
mouse. Since the stimulus was turned off by the nocifensive paw
withdrawal response, the instrument recorded the mechanical pres-
sure that evoked the response. The animals were allowed to
acquaint for 1 h in test compartments with a wire mesh bottom.
After evaluating the baseline values, treatment with glufosinate or
vehicle took place. After 1 day (acute toxicity) or 15 days (chronic
toxicity), their reactivity was measured several times for each
animal and the results were averaged (Salat et al, 2015).
Macrophage depletion
Mice were macrophage-depleted by daily i.p. injection of 20 mg/kg
mouse anti-CSF1R antibodies (clone AFS98; BioXcell) or isotype IgG
control (Sigma-Aldrich). Mice were pretreated for 3 days with anti-
CSF1R before LLC tumor cell injection and then injected 3 times a
week until sacrifice. At the end stage, 300 ll of blood was collected
by retro-orbital bleeding and subjected to hemolysis. Total RNA was
isolated, treated with DNase (Qiagen), and assessed for purity by
spectroscopy. A Bio-Rad iScript reverse transcription kit was used to
make cDNA from 150 ng RNA. TaqMan probe and primers for
CD90.1 were purchased from IDT as follows: Probe 50-/56-FAM/
AGCTTCGCG/ZEN/TCAGC/3IABkFQ/-30, Fwd 50-GGATGAGGGCGA
CTACTT-30 and Rv 50-ACTTGACCAGCTTGTCTCTATAC-30. Analysis
was carried out with a QuantStudio real-time PCR system (Thermo
Fisher). All transcript levels were normalized against the b-actin
expression level and compared to vehicle group.
Statistics
Data entry and all analyses were performed in a blinded fashion.
Statistical analysis was performed using GraphPad Prism software.
Data were tested for normality using the D’Agostino–Pearson
omnibus test (for n > 8) or the Kolmogorov–Smirnov test (for
n ≤ 8) and variation within each experimental group was assessed.
Statistical significance was calculated by two-tailed unpaired t-test
or ANOVA test with Tukey post hoc test. Sample sizes for all experi-
ments were chosen based on previous experiences. Independent
experiments were pooled and analyzed together whenever possible
as detailed in figure legends. Results, represented as means  SEM,
were considered statistically significant as follows: *P < 0.05,
**P < 0.01, ***P < 0.001, ****P < 0.0001. Exact P values and statis-
tical tests are reported for each experiment in Appendix Table S2.
Study approval
Housing and all experimental animal procedures were approved by
the Institutional Animal Care and Research Advisory Committee of
the KU Leuven. For studies on macrophages from PBMCs, buffy
coats were obtained from the local Blood Bank under an Institu-
tional approved agreement (B322201215873 for Leuven and
0070295 for Bari). Additionally, experiments were conformed to the
principles set out in the WMA Declaration of Helsinki and the
Department of Health and Human Services Belmont Report.
Expanded View for this article is available online.
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